



HCV and OUD: Becoming **HEROs**

Melissa Bumgardner, Pharm.D., BCPS

Director of Pharmacy Services

West Hawaii Community Health Center

February 14, 2022

Brief History

- Substance Abuse Services Expansion (SASE) Project
 - Only one X-waivered provider in West Hawai'i in 2015 who planned to retire in 2016
 - WHCHC received HRSA grant to begin MOUD services
 - Integrated program, initiated Fall 2016
 - Administration
 - BH (providers and CM)
 - Medical
 - Clinical pharmacy (and support staff)
 - Nursing
 - Data specialist
 - Billing Supervisor
 - Front Desk – and all staff (to some extent)
 - Over 450 individuals served as of 2022
- Pharmacist-led HCV treatment program
 - 2018: Only two GI providers on Hawaii island following unexpected retirement of Kona provider (Waimea and Hilo)
 - Integrated, pharmacist-led program
 - Consulting hepatologist
 - Pharmacy team: Clinical pharmacist, Prescription coordinator, PA Specialist
 - Medical provider
 - Case management**
 - Contract Pharmacy

HCV Program Highlights

First patient began treatment on 4/16/2019

As of Feb 2022: 68* patients have completed tx

- Screened 4383 patients
- 71 confirmed infections

SVR confirmed for 50 of 67 eligible patients

- 2/17 patients deceased (non-liver related)
- 1/17 declined labs
- 5/17 LTFU (moved, incarcerated, etc.)
- 1/17 did not finish treatment and has detectable HCV RNA

HERO: Health Enhancement to Reduce Opioid-Use-Disorder

Care coordination for HCV testing/cure with concurrent referral/linkage for OUD treatment

Two-year project beginning April 2021

Bonus incentives to use at FQHC discretion – Gift cards


- Completion of HCV screening labs or other testing
- Attending appointments (?)

Core team

- Clinical pharmacists
- MOUD BH Case Manager
- Care Coordination Case Manager
- BH Program Manager
- Data Integrity Manager

How to identify OUD patients?

Workflow



HERO Data 2021

Month	Total	Antibody	Antibody +	RNA	RNA +	Start HCV TX	Finish HCV TX	Refer MOUD	Start MOUD
Jan-21									
Feb-21									
Mar-21									
Apr-21 (BASELINE)	125	75	26	24	16	12	11	113	103
May-21	8	6	1	1	0	0	1	8	3
Jun-21	5	2	1	1	0	1	0	3	1
Jul-21	7	4	1	1	1	0	0	2	2
Aug-21	6	4	0	1*	1*	0	1	3	2
Sep-21	10	5	3	3	2	0	0	5	1
Oct-21	9	4	1	1	1	0	0	4	5
Nov-21	9	3	2	2	1	0	0	8	5
Dec-21	3	2	0	0	0	0	0	2	1
Total	182	105	35	33	21	13	13	148	123
DEFINITIONS									
Month	Total	Antibody	Antibody +	RNA*	RNA +*	Start HCV TX*	Finish HCV TX*	Refer MOUD*	Start MOUD*
activities for the entire month (1-30/31)	# clients in target population within agency	# of hepatitis C antibody tests within target population	# of positive/reactive hepatitis C antibody tests within target population	# of hepatitis C RNA tests within target population	# of positive/detected hepatitis C RNA tests within target population	# of clients who initiated hepatitis C treatment within target population	# of clients who completed hepatitis C treatment within target population	# of clients referred to medication for opioid use disorder within target population	# of clients started medication for opioid use disorder within target population

HERO Data Continued

Month	Total	Antibody	GAP	GAP CLOSUR
Jan-21				
Feb-21				
Mar-21				
Apr-21 (BASELINE)		125		75
May-21		8		6
Jun-21		5	55	52
Jul-21		7	58	54
Aug-21		6	60	55
Sep-21		10	65	56
Oct-21		9	70	57
Nov-21		9	76	63
Dec-21		3	77	52
Total		182		105
DEFINITIONS				
Month	Total	Antibody		
activities for the entire month (1-30/31)	# clients in target population within agency	# of hepatitis C antibody tests within target population		

Quantifying Program Impact

- 13/68 (19%) HCV patients were dually diagnosed
 - 4/13 (30%) did not obtain SVR labs
 - 13/63 (20%) non-dual patients did not obtain SVR labs
- Of the 25 patients who were counted as “gap closure”
 - 14 were lost-to-follow-up (2 year look back)
 - 11 obtained HCV screening test (14%)

Barriers to Laboratory Testing



Needle “triggers” memory of previous substance use (former PWID) – risk of relapse

Venous trauma – lack of venous access (former PWID)

Transportation

Laboratory requisition error

Frequent testing (in cases of relapse)

HERO 2022

BH CM alerts pharmacy team of all new induction patients

- Pharmacist adds patient to tracker
- Pharmacist orders labs if needed – nurse visit standing orders

CC CM “scrubs” schedules and tracker for upcoming appts

- Pairs with appt to offer incentives
- Follows for results and incentive delivery
- Assists in coordination of care of chronic HCV patients

ODD Medical Providers provides lab opportunity during appointment

Identification of lab that will provide alternate site blood draw